|Videos|November 4, 2017

Providers: Be Assertive When Recommending Flu Vaccination to Older Adults

William Schaffner, MD, explains how health care providers can work towards getting patients who are aged 65 and older to receive a flu shot.

William Schaffner, MD, medical director for the National Foundation for Infectious Diseases’ (NFID) and infectious disease physician at Vanderbilt, explains how health care providers can work towards getting patients who are aged 65 and older to receive a flu shot.

Interview Transcript (modified slightly for readability):

[So, what about] the role of the provider, and physicians for sure, but also pharmacists, and everyone else who deals with the public? It is said that we should recommend influenza vaccine to everyone because the recommendations say that everyone older than 6 months of age should be vaccinated each and every year against influenza.

But a recommendation can be made very casually. ‘Oh, Tom, it’s that time of the year. You ought to think about getting your flu vaccine.’ That’s a recommendation? That’s giving the patient permission to decline vaccination. We don’t say that about the treatment of diabetes. ‘Oh, you ought to think about getting your diabetes treated, Tom.’

We need to insist on vaccination. We need to say, ‘It’s that time of the year; we vaccinate everyone in our practice.’ And if you get pushback, look at the patient in a kind of an alarmed way and say, ‘I’ve been vaccinated. My whole family has been vaccinated. Everybody in the office has been vaccinated. Tom, we’re going to vaccinate you before you go home.’ Because it’s so important to do everything we can to prevent influenza, and if we are more assertive rather than just casually recommending, I think we’ll vaccinate many, many more people.

You’d be surprised how many people have a health care encounter during the fall and leave the doctor’s office, the pharmacy, or wherever, unvaccinated. That shouldn’t happen.”


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.